You likely know the expression, Pay It Forward. It’s an important concept for any kind of social awareness, but it can carry special meaning as well in the breast cancer world, particularly in research.
That’s because so much of today’s important breakthroughs are built not only on yesterday’s participation of other patients, but, of course, the work of other researchers.
It’s a sentiment Dr. Luca Gianni not only knows well, but also puts into practice every day.
As you’ll hear, in this important and engaging conversation, Dr. Gianni remains grateful to his mentor – Dr. Gianni Bonadonna – who brought him into the National Institute for the Study and Treatment of Cancer in Milan, Italy some 40 years ago. Based on what he learned there, Dr. Gianni has since delivered numerous breakthroughs in cancer research.
Onea main treatment – particularly in women with locally advanced or inflammatory HER2-positive breast cancer.
Now he is taking that same mindset – focus on early treatment – to drive his research in an important different direction: To help identify triple negative breast cancer patients most likely to benefit from checkpoint inhibitor therapy before beginning the treatment and those who will do well with chemotherapy alone. Not only would this help find patients with greater likelihood for an improved outcome, of course, but it also could help reduce the extreme costs and toxicity side effects for patients unlikely to benefit.
More about Dr. Gianni: He is Director of the Department of Medical Oncology and the head of the Project of Development of New Drugs and Innovative Therapies in Solid Tumors at the San Raffaele Scientific Institute in Milan. He is also Cofounder and President of the Michelangelo Foundation, a non-profit organization designed to advance research in oncology, and chairman of the Michelangelo Breast Cancer Study Group. Dr. Gianni has received several grants and research support, and was awarded the “Gianni Bonadonna Award and Fellowship” by the American Society of Clinical Oncology in 2011 – yes, an award named after his mentor. He also has been a BCRF Investigator since 2018.
I connected with Dr. Gianni in his lab in Italy, which left me envious of course that the conversation occurred, as you’ll hear, via computer, rather than in person – say, in a local Milan cafe… Well, we can’t have everything
Improving Treatments for Invasive Lobular Carcinoma with Dr. Adrian Lee
Improving Breast Cancer Radiation Treatments with Dr. Rachel Jimenez
The Effects of a High-Fiber Diet in Early-Stage Breast Cancer with Dr. Laura Esserman
BCRF 2023 New York City Symposium
Investigating Novel Biomarkers for Personalized Treatments with Dr. Roisin Connolly
Reflecting on Thirty Years of Progress with Dr. Larry Norton
The Progress and Future of Breast Cancer Vaccines with Dr. Nora Disis
The Future of Breast Cancer Risk Prediction with Dr. Regina Barzilay
Lowering Barriers to Breast Cancer Genetic Testing with Dr. Susan Domchek
Studying Breast Cancer Risk in Asian American Communities with Dr. Scarlett Gomez
Bridging the Gap Between the Lab and Patient Care with Dr. Ian Krop
Understanding and Targeting Triple-Negative Breast Cancer with Dr. Jill Bargonetti
Exploring Social Determinants of Health in Breast Cancer Care with Dr. Sonya Reid
BCRF Investigators Discuss the Latest in Breast Cancer Research at 2022 Symposium
Finding and Targeting “Sleeping” Cancer Cells with Dr. Angela DeMichele
Investigating What Drives Recurrence and Metastasis with Dr. Christina Curtis
The Impact of Chemotherapy on Accelerated Aging in Elderly Patients with Dr. Hyman Muss
Advancing Breast Cancer Immunotherapy and Decoding Treatment Resistance with Dr. Hope Rugo
Improving Breast Cancer Care and Narrowing the Health Disparities Gap with Dr. Dawn Hershman
The Urgent Need for Triple-Negative Breast Cancer Breakthroughs with Dr. Elisa Port
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
2 Peas in A Pod
LMU An introduction to Bohmian Mechanics